NEW YORK (
CHANGE IN RATINGS
Abercrombie & Fitch
upgraded at Morgan Stanley from Equal-weight to Overweight. $56 price target. Stock appears attractive, on a sum-of-the-parts analysis.
rated new Buy at Sterne Agee. $222 price target. Recent underperformance has created an attractive buying opportunity.
Clear Channel Outdoor
upgraded at Wells from Market Perform to Outperform. Company has late-cycle exposure to the advertising recovery.
upgraded at Goldman to Buy. Estimates also raised, as the company should continue to grow sales in the SaaS market. $102 price target.
Great Plains Energy
downgraded at Keybanc from Buy to Hold. Valuation call, as the stock has moved up through the $19.50 price target.
rated new Buy at Goldman. Company was also placed on the Conviction List, with a $56 price target. Appears to be in the early stages of a sales growth cycle.
upgraded at Goldman from Neutral to Buy. $66 price target. Market is not yet pricing in the potential for positive earnings surprises.
downgraded at Keybanc from Buy to Hold. Company is guiding for flatter margins in the second half of the year.
rated new Neutral at Goldman Sachs. Sales expectations appear high, though the company could still deliver another year of 20% earnings growth. $27 price target.
rated new Equal-weight at Morgan Stanley. $69 price target. Stock is already pricing in leverage to recovery in industrial production. Equal-weight rating.
coverage assumed at Citi. SAPE upgraded to Buy from Hold. As media investors become more focused on Sapient's digital marketing exposure, valuation will improve, Citigroup said. Price target jumped to $14.50 from $11.
added to Conviction Buy list at Goldman Sachs. Company is positioned well to benefit from a cyclical recovery in technology and marketing spending. $13 price target.
upgraded at Citi to Buy from Neutral. The successfully executed $1 billion equity raise removed the key overhang for the stock.
rated new Outperform at Oppenheimer. $40 price target. Consumer business has a robust pipeline of new products.
STOCK COMMENTS / EPS CHANGES
cut from Conviction Buy list at Goldman. See more near-term upside in SAPE. $50 price target.
estimates boosted at Morgan Stanley through 2011. Company has strong earnings momentum, despite uncertainty in the Gulf of Mexico. Equal-weight rating.
target, estimates boosted Citi. ARW price target jumped to $43 from $36.50 as 1Q10 earnings beat and optimistic outlook. 2010 and 2011 EPS estimates lifted to $3.16 and $3.20, respectively. Maintain Buy rating.
numbers raised at UBS. Shares of ARW now seen reaching $36. Estimates also increased, to match the company's new guidance. Buy rating.
estimates cut at UBS through 2011. Company is seeing lower earnings in China and Venezuela, while facing extra charges for its internal investigation. Buy rating and $40 price target.
estimates, target lowered at Goldman. Shares of BAX now seen reaching $52. Estimates also reduced, given slower expected growth in the plasma business. Neutral rating.
estimates lowered at UBS through 2011. Recall of the Colleague pump will hurt sales. Buy rating and $60 price target.
estimates reduced at Morgan Stanley through 2011. Company to see an impact from healthcare reform. Overweight rating.
price target higher at BofA/Merrill, jumped to $7 from $4.50 as balance sheet improves. Reiterate Neutral rating.
CB Richard Ellis
numbers boosted at Goldman. Shares of CBG now seen reaching $21. Estimates also upped, given improved brokerage activity. Buy rating.
estimates boosted at UBS through 2011. Company boosted its production guidance. Neutral rating and $25 price target.
estimates raised at Goldman through 2012. Company is realizing higher margins. Neutral rating and $67 price target.
added to Top Picks List at FBR. Profitability is being pushed out, but the thesis remains intact. $6.50 price target.
Dick's Sporting Goods
numbers boosted at FBR. Shares of DKS now seen reaching $33. Estimates were also upped, following positive channel checks. Outperform rating.
estimates increased at Morgan Stanley. GILD estimates were raised through 2012. Company continues to generate solid cash flow. Overweight rating and $48 price target.
target, estimate higher at BofA/Merrill. HT price target lifted to $7 from $6. Estimates raised through 2011 on robust NY RevPAR. Maintain Buy.
estimates lowered at Morgan Stanley through 2012. Company is facing a higher pension cost at Cadbury. Overweight rating and $32 price target.
target, estimates lower at BofA/Merrill. KG price target trimmed by a dollar to $14. Share have been weak lately due to slow launch of Embeda and negative FDA panel meeting on Acurox. 2010 and 2011 estimates lowered. Reiterate Buy.
estimates, target upped at Goldman. MCK estimates were boosted through 2013. Company raised forward guidance. Neutral rating and new $70 price target.
estimates, target increased at FBR. MSCC estimates were raised through 2011. Recent acquisition should boost growth. Outperform rating and new $25 price target.
estimates increased at UBS through 2011. Stock buyback and debt refinancing should boost earnings. Buy rating and $36 price target.
estimates increased at Goldman through 2012. Company is seeing higher margins, but lower sales. Sell rating and $22 price target.
numbers raised at FBR. Shares of PFG now seen reaching $32. Estimates also increased, given better margins and asset inflows. Market Perform rating.
This article was written by a staff member of TheStreet.com.